Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Cross Infection D003428 9 associated lipids
Urethritis D014526 9 associated lipids
Infant, Newborn, Diseases D007232 9 associated lipids
Lymphadenitis D008199 8 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Enteritis D004751 8 associated lipids
Leprosy D007918 8 associated lipids
Opportunistic Infections D009894 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Gonorrhea D006069 7 associated lipids
Serum Sickness D012713 7 associated lipids
Cytomegalovirus Infections D003586 7 associated lipids
Mucositis D052016 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Chlamydia Infections D002690 7 associated lipids
Pelvic Pain D017699 7 associated lipids
Corynebacterium Infections D003354 7 associated lipids
Chronic Disease D002908 7 associated lipids
Keratitis D007634 7 associated lipids
Stomach Diseases D013272 7 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Skin Ulcer D012883 6 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Mycoplasmatales Infections D009180 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Syphilis D013587 6 associated lipids
Dysentery, Bacillary D004405 6 associated lipids
Whooping Cough D014917 6 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Protozoan Infections D011528 6 associated lipids
Lyme Disease D008193 5 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Splenic Diseases D013158 5 associated lipids
Prostatitis D011472 5 associated lipids
Rickettsia Infections D012282 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Dog Diseases D004283 5 associated lipids
Infectious Mononucleosis D007244 5 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Arrieta A et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. 2003 Antimicrob. Agents Chemother. pmid:14506028
Nilius AM et al. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. 2001 Antimicrob. Agents Chemother. pmid:11408246
Maves RC et al. Antimicrobial susceptibility of Brucella melitensis isolates in Peru. 2011 Antimicrob. Agents Chemother. pmid:21199926
Wondrack L et al. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. 1996 Antimicrob. Agents Chemother. pmid:8849266
Ishida K et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. 1994 Antimicrob. Agents Chemother. pmid:8031048
Hauser C et al. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. 2015 Antimicrob. Agents Chemother. pmid:25547354
Nash KA and Inderlied CB Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. 1995 Antimicrob. Agents Chemother. pmid:8592991
Bohte R et al. Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. 1995 Antimicrob. Agents Chemother. pmid:8593024
Salman S et al. Pharmacokinetic properties of azithromycin in pregnancy. 2010 Antimicrob. Agents Chemother. pmid:19858250
Nalca Y et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. 2006 Antimicrob. Agents Chemother. pmid:16641435
Asgrimsson V et al. Novel effects of azithromycin on tight junction proteins in human airway epithelia. 2006 Antimicrob. Agents Chemother. pmid:16641453
Ulrich M et al. Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. 2005 Antimicrob. Agents Chemother. pmid:16304181
Chave JP et al. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. 1992 Antimicrob. Agents Chemother. pmid:1324635
Derouin F et al. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1324642
Vallée E et al. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. 1992 Antimicrob. Agents Chemother. pmid:1324644
Merchan LM et al. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. 2015 Antimicrob. Agents Chemother. pmid:25385115
Mertens JC et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. 1992 Antimicrob. Agents Chemother. pmid:1324645
Dubois J et al. In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates. 2015 Antimicrob. Agents Chemother. pmid:25348534
Ednie LM et al. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. 1996 Antimicrob. Agents Chemother. pmid:8843313
Pajukanta R et al. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. 1992 Antimicrob. Agents Chemother. pmid:1329617
Bonnet M and Van der Auwera P In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. 1992 Antimicrob. Agents Chemother. pmid:1329619
Koletar SL et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. 1999 Antimicrob. Agents Chemother. pmid:10582873
Nicolau DP et al. Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. 1999 Antimicrob. Agents Chemother. pmid:10582906
Dagan R et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. 2000 Antimicrob. Agents Chemother. pmid:10602721
McGannon CM et al. Different classes of antibiotics differentially influence shiga toxin production. 2010 Antimicrob. Agents Chemother. pmid:20585113
Koetsveld J et al. Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents. 2017 Antimicrob. Agents Chemother. pmid:28674060
Clark C et al. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. 2002 Antimicrob. Agents Chemother. pmid:12183253
Yamada K et al. Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii. 2013 Antimicrob. Agents Chemother. pmid:23733468
Blandizzi C et al. Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients. 2002 Antimicrob. Agents Chemother. pmid:11959610
Moon JE et al. Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. 2006 Antimicrob. Agents Chemother. pmid:16723556
Steele-Moore L et al. In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. 1999 Antimicrob. Agents Chemother. pmid:10383373
Bogdanovich T et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. 2006 Antimicrob. Agents Chemother. pmid:16723565
Kosowska-Shick K et al. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. 2006 Antimicrob. Agents Chemother. pmid:16723567
Ng LK et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. 2002 Antimicrob. Agents Chemother. pmid:12183262
Matsui H et al. Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium. 2005 Antimicrob. Agents Chemother. pmid:16048953
Prunier AL et al. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. 2002 Antimicrob. Agents Chemother. pmid:12183270
Carannante A et al. Changing antimicrobial resistance profiles among Neisseria gonorrhoeae isolates in Italy, 2003 to 2012. 2014 Antimicrob. Agents Chemother. pmid:25070110
Collins SA et al. Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. 2017 Antimicrob. Agents Chemother. pmid:27919896
Walsh M et al. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:3038010
Zhang Y et al. Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents. 2017 Antimicrob. Agents Chemother. pmid:27855081
Waites KB et al. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. 2017 Antimicrob. Agents Chemother. pmid:27855075
Scorneaux B et al. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. 1996 Antimicrob. Agents Chemother. pmid:8723471
Galarza PG et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. 2010 Antimicrob. Agents Chemother. pmid:20123998
Jaruratanasirikul S et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. 1996 Antimicrob. Agents Chemother. pmid:8851625
Shimuta K et al. Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance. 2013 Antimicrob. Agents Chemother. pmid:23939890
Carryn S et al. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. 2002 Antimicrob. Agents Chemother. pmid:12069960
Babl FE et al. Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. 2002 Antimicrob. Agents Chemother. pmid:12069974
D'Ignazio J et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. 2005 Antimicrob. Agents Chemother. pmid:16189077
Tissi L et al. In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. 1995 Antimicrob. Agents Chemother. pmid:8540695
Sahm DF et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. 2001 Antimicrob. Agents Chemother. pmid:11257013
Jensen JS et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains. 2014 Antimicrob. Agents Chemother. pmid:24637681
Koirala KD et al. Highly resistant Salmonella enterica serovar Typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. 2012 Antimicrob. Agents Chemother. pmid:22371897
Bielaszewska M et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. 2012 Antimicrob. Agents Chemother. pmid:22391549
Ohtani H et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. 2000 Antimicrob. Agents Chemother. pmid:10991836
Nagai K et al. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. 2001 Antimicrob. Agents Chemother. pmid:11600391
Erhardt W et al. Establishing criteria for assessment of efficacy of antimicrobial agents in acute otitis media. 2000 Antimicrob. Agents Chemother. pmid:11012390
Klemens SP and Cynamon MH Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. 1994 Antimicrob. Agents Chemother. pmid:7986001
Andersen SL et al. Efficacy of azithromycin as a causal prophylactic agent against murine malaria. 1994 Antimicrob. Agents Chemother. pmid:7986022
Cigana C et al. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. 2007 Antimicrob. Agents Chemother. pmid:17210769
Pruul H and McDonald PJ Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. 1992 Antimicrob. Agents Chemother. pmid:1317141
Brown BA et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. 1992 Antimicrob. Agents Chemother. pmid:1317144
Farrell DJ et al. Results from the Solithromycin International Surveillance Program (2014). 2016 Antimicrob. Agents Chemother. pmid:27044551
Niki Y et al. In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. 1994 Antimicrob. Agents Chemother. pmid:7840560
Welsh LE et al. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1318677
Freeman CD et al. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. 1994 Antimicrob. Agents Chemother. pmid:7840585
Caronzolo D et al. Effect of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, on experimental Chlamydophila pneumoniae infection. 2006 Antimicrob. Agents Chemother. pmid:17005805
Nagai K et al. Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries. 2002 Antimicrob. Agents Chemother. pmid:11796375
Miltner EC and Bermudez LE Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10858369
Sugimura M et al. Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. 2008 Antimicrob. Agents Chemother. pmid:18676884
Liu P et al. Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. 2011 Antimicrob. Agents Chemother. pmid:21859932
Goldstein EJ et al. Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. 1995 Antimicrob. Agents Chemother. pmid:7625795
Sjölund-Karlsson M et al. Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States. 2011 Antimicrob. Agents Chemother. pmid:21690279
Ramya TN et al. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum. 2007 Antimicrob. Agents Chemother. pmid:17060533
Su XH et al. Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914). 2015 Antimicrob. Agents Chemother. pmid:26482313
Shima K et al. Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia. 2013 Antimicrob. Agents Chemother. pmid:23478971
Pfefferkorn ER and Borotz SE Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. 1994 Antimicrob. Agents Chemother. pmid:8141576
Bermudez LE et al. Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells. 1994 Antimicrob. Agents Chemother. pmid:8067766
Agacfidan A et al. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. 1993 Antimicrob. Agents Chemother. pmid:8239579
Goodman CD et al. Chemobiosynthesis of new antimalarial macrolides. 2013 Antimicrob. Agents Chemother. pmid:23208707
Tomazic J et al. In vivo administration of azithromycin affects lymphocyte activity in vitro. 1993 Antimicrob. Agents Chemother. pmid:8239585
Rakita RM et al. Intracellular activity of azithromycin against bacterial enteric pathogens. 1994 Antimicrob. Agents Chemother. pmid:7810998
Kim MK et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. 2002 Antimicrob. Agents Chemother. pmid:12234843
Meyer AP et al. Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. 1993 Antimicrob. Agents Chemother. pmid:8285612
Imamura Y et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. 2005 Antimicrob. Agents Chemother. pmid:15793115
Shima K et al. Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis. 2011 Antimicrob. Agents Chemother. pmid:21321137
Chinh NT et al. Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers. 2011 Antimicrob. Agents Chemother. pmid:21730120
Ma Q et al. A Waterborne Outbreak of Shigella sonnei with Resistance to Azithromycin and Third-Generation Cephalosporins in China in 2015. 2017 Antimicrob. Agents Chemother. pmid:28373192
Wind CM et al. A Case-Control Study of Molecular Epidemiology in Relation to Azithromycin Resistance in Neisseria gonorrhoeae Isolates Collected in Amsterdam, the Netherlands, between 2008 and 2015. 2017 Antimicrob. Agents Chemother. pmid:28373191
Karlowsky JA et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. 2003 Antimicrob. Agents Chemother. pmid:12760850
Yamaguchi H et al. Chlamydia pneumoniae resists antibiotics in lymphocytes. 2003 Antimicrob. Agents Chemother. pmid:12760877
Kutlin A et al. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. 2002 Antimicrob. Agents Chemother. pmid:11796350
Jacks SS et al. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. 2003 Antimicrob. Agents Chemother. pmid:12709351
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Welsh L et al. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8787907
Schroeck JL et al. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. 2015 Antimicrob. Agents Chemother. pmid:25870064
Waites KB et al. In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas. 2015 Antimicrob. Agents Chemother. pmid:25824220
Nagaoka K et al. Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23380724
Edelstein PH et al. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. 2001 Antimicrob. Agents Chemother. pmid:11451675
Matzneller P et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. 2013 Antimicrob. Agents Chemother. pmid:23357769
Patel KB et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891147